INVO Fertility receives Nasdaq notice over delayed SEC filings
Seeking Alpha News (Tue, 2-Jun 5:05 PM ET)
INVO Fertility Receives Nasdaq Notification Regarding Late Filing of Quarterly Report on Form 10-Q
Globe Newswire (Tue, 2-Jun 4:50 PM ET)
INVO BioScience GAAP EPS of -$214.64, revenue of $6.84M
Seeking Alpha News (Tue, 2-Jun 12:44 PM ET)
INVO Fertility Announces Fiscal Year 2025 Financial Results
Globe Newswire (Tue, 2-Jun 8:30 AM ET)
INVO Fertility Receives Nasdaq Notification Regarding Late Filing of Annual Report on Form 10-K
Globe Newswire (Wed, 29-Apr 4:05 PM ET)
INVO Fertility Announces a 1:5 Reverse Stock Split Effective Pre-Market Opening on March 27, 2026
Globe Newswire (Wed, 25-Mar 8:30 AM ET)
INVO Fertility Inc is a healthcare services fertility company dedicated to expanding assisted reproductive technology (ART) care to patients in need. It is offering the intravaginal culture (IVC) procedure enabled by INVOcell medical device (INVOcell). The INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. The company's segments include: The Clinics Services operating segment consisting of financial information for WFI and the Atlanta Clinic; The INVOcell Device operating segment consisting of financial information relating to the manufacture and sales of the INVOcell; and The Therapeutics segment consisting of financial information relating to acquired subsidiary, NTI.
Invo Fertility trades on the NASDAQ stock market under the symbol IVF.
As of June 5, 2026, IVF stock price declined to $1.59 with 115,986 million shares trading.
IVF has a beta of 0.54, meaning it tends to be less sensitive to market movements. IVF has a correlation of 0.00 to the broad based SPY ETF.
IVF has a market cap of $24.06 million. This is considered a Sub-Micro Cap stock.
Last quarter Invo Fertility reported $2 million in Revenue and -$40.40 earnings per share. This fell short of revenue expectation by $-344,000 and missed earnings estimates by -$18.40.
IVF has underperformed the market in the last year with a price return of -99.1% while the SPY ETF gained +25.6%. IVF has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -63.4% and -3.0%, respectively, while the SPY returned +8.5% and -1.1%, respectively.
IVF support price is $1.50 and resistance is $1.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IVF shares will trade within this expected range on the day.
